By Katherine Hamilton

Standard BioTools plans to cut 15% of its global staff as part of a restructuring plan.

The provider of life-science tools is reducing its workforce to improve operational efficiency and lower operating costs in line with current revenue projections, it said in a filing Wednesday.

Expenses related to the job cuts are expected to be about $7.5 million. Those costs should be payable over the next several months, Standard BioTools said.

The San Francisco company is anticipating lower revenue because of funding pressures at the National Institutes of Health, it said in its last three financial reports. It expects the decline in its Americas academic revenue to decline by high single-digit millions.

Standard BioTools last quarter also announced the sale of SomaLogic, which is planned to close in the first half of 2026. The company said in August it expects revenue from continuing operations to be $78 million to $83 million for the full year, whereas combined revenue was projected to be $165 million to $175 million.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

September 17, 2025 16:59 ET (20:59 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.